title: Preischemic bolus application of piroximone studied on the isolated rabbit heart--a second look including biochemical data.
abstract: In a randomized prospective experimental study on 48 adult white Elco rabbits biochemical and rhythmic changes after bolus administration of the phosphodiesterase inhibitor piroximone were investigated using a working heart model. The treatment group (n = 21) intravenously received 1 mg/kg of piroximone 15 min before thoracotomy. Twenty-three untreated hearts served as the control group. From 6 hearts of each group myocardial biopsies were taken before ischemia, 4 (2/2) hearts were excluded. Hemodynamic results of a previous study with an identical protocol were reanalyzed; a biochemical analysis of myocardial high-energy phosphates was investigated after 60 min of global ischemia and at the end of the experiments after 45 min of reperfusion. Already prior to ischemia, in the treatment group depletion of high-energy phosphates was detected. After 60 min of ischemia during early reperfusion in the treatment group ATP and creatine phosphate depletion became even more evident and increased until the end of the experiments. The incidence of reperfusion-induced arrhythmias was significantly lower in the treatment group. Consequently these results and the hemodynamic results of prior studies indicate a possible positive effect of piroximone during the early reperfusion period by optimizing hemodynamics and arrhythmias.
authors.affiliation: Department of Cardiothoracic Surgery, General Hospital Vienna, Austria.
authors.forename: B
authors.initials: B
authors.lastname: Podesser
authors.forename: W
authors.initials: W
authors.lastname: Zwölfer
authors.forename: M
authors.initials: M
authors.lastname: Zegner
authors.forename: G
authors.initials: G
authors.lastname: Koci
authors.forename: E
authors.initials: E
authors.lastname: Wolner
authors.forename: G
authors.initials: G
authors.lastname: Wollenek
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism*; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000453:epidemiology / Q000209:etiology; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D007093:Imidazoles / Q000494:pharmacology*; D066298:In Vitro Techniques; D015994:Incidence; D017202:Myocardial Ischemia / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D015425:Myocardial Reperfusion; D015428:Myocardial Reperfusion Injury / Q000150:complications; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D010725:Phosphocreatine / Q000378:metabolism*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011817:Rabbits
chemical_list: D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D010725:Phosphocreatine; C039686:piroximone; D000255:Adenosine Triphosphate